Penn Medicine News Release
Stephen Schuster, MD, an associate professor in the division of
Hematology/Oncology, delivered a plenary presentation on Sunday during the
annual meeting of the American Society of Clinical Oncology in Orlando
describing the results of the Phase III trial of a personalized vaccine for
follicular lymphoma patients who went into remission following chemotherapy.
Patients who received a vaccine prepared from their own freshly isolated tumor
cells combined with an immune-stimulating agent had a median time to relapse of
44.2 months, compared with 30.6 months for patients treated with the control
vaccine... Read More
The findings, hailed as a major advance in personalized cancer therapy,
were covered by NCI Bulletin, USA Today, Associated Press, Wall Street
Journal, New York Times, ABC News (via Med Page Today),
Bloomberg News, Houston Chronicle, Atlanta Journal Constitution
and MSN.com (via Health Day News), and other media outlets.
Find a Doctor/Researcher
Make an Appointment
Refer a Patient
Make a Gift
Penn Cancer Network
